AMERICAN SOCIETY OF CLINICAL ONCOLOGY

Jacobio Pharmaceuticals presented glecirasib's efficacy in treating KRAS G12C mutated pancreatic and other solid tumors at ASCO GI 2024. With a 48% cORR and 90% DCR in evaluable patients, glecirasib shows promise over standard treatments, supported by safety and tolerability data. It received BTD for pancreatic cancer, aiming to expedite its development and patient access.

Zymeworks Inc. updates on 2024-2025 strategic priorities, including zanidatamab's Phase 3 trial data expected in 2024, regulatory reviews, and IND applications for new candidates. With $455M cash resources, the company plans to extend its R&D efforts into 2027, focusing on ADCs and multispecific antibody therapeutics.

GSK and Hansoh Pharma announced an exclusive license agreement for HS-20093, a B7-H3 targeted antibody-drug conjugate, showing promising clinical activity in lung cancer. GSK gains worldwide rights (excluding China) for development and commercialization, with Hansoh eligible for up to $1.525 billion in milestones and royalties. HS-20093 is in phase I/II trials in China, with GSK planning phase I trials outside China in 2024.

A study introduces an AI platform, TrialTranslator, to assess individual patient benefits from clinical trial therapies, using real-world data to emulate trials. It aims to improve treatment decisions and identify non-responsive patient groups, suggesting prognosis over eligibility criteria for trial participation. Supported by NIH grants.

Dirk Reitsma highlighted inclusivity challenges in oncology trials at Pharma 2023, emphasizing restrictive eligibility criteria and complex protocols. Broadening criteria, such as allowing brain metastases and considering HIV status, could enhance diversity. Performance status thresholds and other factors like side effects and drug shortages also impact trial participation and design.

HER2-positive breast cancer, known for its aggressive nature and poor prognosis, benefits significantly from neoadjuvant and adjuvant treatments, including chemotherapy and HER2 blockers like trastuzumab. Achieving a pathological complete response (pCR) post-treatment is crucial for improved survival. The review emphasizes the importance of selecting appropriate systemic treatments based on tumor and lymph node staging to optimize outcomes, highlighting the role of dual HER2 blockage and the potential for de-escalating adjuvant therapy in certain cases.

Experts predict advancements in lung cancer treatment, emphasizing the importance of early screening, understanding immunotherapy resistance, and developing precision medicine. They foresee improvements in targeted therapies and the potential for immunotherapy in cancer prevention, aiming for longer-term benefits and cures within the next decade.

At the 2023 ASCO meeting, Dr. Shanshan Wang presented a subpopulation analysis of the ARASENS study on darolutamide's efficacy and safety in Chinese patients with mHSPC. Darolutamide + ADT + docetaxel reduced death risk by 36% (HR 0.64) vs placebo, with similar adverse events. Results align with the overall ARASENS population findings.